Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2026DermatitisOpen Access

Inadequate Disease Control with Current Therapies Among Patients with a History of Moderate-to-Severe Atopic Dermatitis

View Full Paper
Ask AI
Bookmark
Share

Authors

PLPeter LioAGAlexandra GolantRCRaj Chovatiya

Discussion

Loading...

Member takes

Overview

Cross-sectional survey reveals inadequate disease control in nearly one-third of adults with moderate-to-severe atopic dermatitis, highlighting substantial unmet treatment needs.

Key Points

  • To evaluate disease control, quality-of-life impact, and symptom burden among adults with moderate-to-severe atopic dermatitis receiving topical or systemic treatments.
  • Analyzed data from the Adelphi Atopic Dermatitis Disease Specific Programme, a cross-sectional real-world survey of US adults conducted between August 2022 and March 2023.
  • Sampled 619 patients (mean age 40.5 years, 50% female) receiving topical-only therapy or systemic therapies (conventional corticosteroids/immunosuppressants or advanced biologics/JAK inhibitors) with or without topicals.
  • Assessed disease control via physician report and evaluated outcomes using the Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), and Work Productivity and Activity Impairment (WPAI-AD).
  • Uncontrolled atopic dermatitis was present in 30.2% of patients overall, representing 36.4% of those receiving topicals alone and 63.6% of those receiving systemic therapies with or without topicals.
  • Patients with uncontrolled disease on systemics had higher disease burden (DLQI 10.0, POEM 11.8, WPAI activity impairment 30.9, absenteeism 12.1) than those on topical-only regimens (DLQI 3.3, POEM 8.7, WPAI activity impairment 13.9, absenteeism 0).
  • Controlled disease was consistently linked with lower symptom scores across all treatment groups, though conventional systemics were associated with greater overall burden than advanced systemics.

Cite This Study

Lio et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4346b95aff0620eb9e5https://doi.org/10.1177/17103568261472596
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Atopic Dermatitis Treatment with Topical Therapy Alone Results in Persistent Elevated Disease Severity and High Disease Control Dissatisfaction: Real-World Health Care Professional and Patient Perspectives2024
  2. 2Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials2026
  3. 3Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study2024 · 12 citations
  4. 448-Week Real-World Atopic Dermatitis Study on Minimal Disease Activity, Associated Factors, and Agreement Between Clinician- and Patient-Reported Outcomes2026
  5. 5The ChinaSTAD Chinese Registry in Patients with Moderate-To-Severe Atopic Dermatitis Not Controlled by Topical Therapy: Baseline Characteristics, Disease Burden and Treatment2025